Recent Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)
A number of research firms have changed their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX): 12/23/2024 – Neurocrine Biosciences had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock. 12/23/2024 – Neurocrine Biosciences had its price target raised by analysts at Barclays PLC […]
More Stories
7 Best TextNow Alternatives for Free Calling in 2026
Free calling apps like TextNow are being widely used today for smooth global communication without needing extra hardware and software....
Trump Says US Has Seized Oil Tanker Off Coast of Venezuela
By Jack Phillips President Donald Trump said on Dec. 10 that the United States seized an oil tanker off the...
Land Along Southern Border Is Transferred to Navy to Become Part of ‘National Defense Area’
By Jacob Burg The Trump administration said on Dec. 10 that it would transfer roughly 760 acres of public land...
We’ve Just Seen the Best Quarter in 3 Years (In Revenues) or 4 Years (Earnings)
By Louis Navellier I wrote this last weekend aboard the forty-fourth Forbes Cruise for Investors, where there was a high...
New Bipartisan Bills Aim to Raise Penalties for Online Child Abuse, Sextortion
By Savannah Hulsey Pointer Lawmakers announced on Dec. 9 three new bipartisan bills to address online violence and sexual abuse...
British Soldier Killed in Ukraine Watching Training Exercise
By Jill McLaughlin A British soldier was killed in Ukraine on Dec. 9 while watching a training exercise, the UK...